Patents by Inventor Sahori Namiki

Sahori Namiki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-BST2 ANTIBODY
    Publication number: 20130336967
    Abstract: BST2 antibodies were selected by using as an indicator the binding between BST2 antibodies and various splicing variants of human BST2 antigen. As a result, the present inventors successfully obtained BST2 antibodies that specifically recognize BST2D, which has been reported to be expressed at high levels in cancer cells. The antibodies of the present invention specifically bind to cells expressing BST2D. Non-specific antibody binding to non-target tissues, which results in the decrease of antibody concentration in blood, can be prevented by using the antibodies of the present invention therapeutically. Alternatively, the present invention provides diagnostic agents comprising an antibody of the present invention, which specifically detect tissues expressing BST2D.
    Type: Application
    Filed: August 22, 2013
    Publication date: December 19, 2013
    Applicants: CHUGAI SEIYAKU KABUSHIKI KAISHA, SBI BIOTECH CO., LTD.
    Inventors: YUMIKO KAMOGAWA, SAHORI NAMIKI, MINKWON CHO, KOJI ISHIDA
  • Anti-BST2 antibody
    Patent number: 8529896
    Abstract: BST2 antibodies were selected by using as an indicator the binding between BST2 antibodies and various splicing variants of human BST2 antigen. As a result, the present inventors successfully obtained BST2 antibodies that specifically recognize BST2D, which has been reported to be expressed at high levels in cancer cells. The antibodies of the present invention specifically bind to cells expressing BST2D. Non-specific antibody binding to non-target tissues, which results in the decrease of antibody concentration in blood, can be prevented by using the antibodies of the present invention therapeutically. Alternatively, the present invention provides diagnostic agents comprising an antibody of the present invention, which specifically detect tissues expressing BST2D.
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: September 10, 2013
    Assignees: SBI Biotech Co., Ltd., Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yumiko Kamogawa, Sahori Namiki, Minkwon Cho, Koji Ishida
  • ANTI-BST2 ANTIBODY
    Publication number: 20100278832
    Abstract: BST2 antibodies were selected by using as an indicator the binding between BST2 antibodies and various splicing variants of human BST2 antigen. As a result, the present inventors successfully obtained BST2 antibodies that specifically recognize BST2D, which has been reported to be expressed at high levels in cancer cells. The antibodies of the present invention specifically bind to cells expressing BST2D. Non-specific antibody binding to non-target tissues, which results in the decrease of antibody concentration in blood, can be prevented by using the antibodies of the present invention therapeutically. Alternatively, the present invention provides diagnostic agents comprising an antibody of the present invention, which specifically detect tissues expressing BST2D.
    Type: Application
    Filed: October 16, 2008
    Publication date: November 4, 2010
    Inventors: Yumiko Kamogawa, Sahori Namiki, Minkwon Cho, Koji Ishida